130 related articles for article (PubMed ID: 15317829)
21. Pharmacokinetics of difloxacin in goats.
Atef M; el-Banna HA; Abd El-Aty AM; Goudah A
Dtsch Tierarztl Wochenschr; 2002 Jul; 109(7):320-3. PubMed ID: 12161971
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin.
Abou-Auda HS; Mustafa AA; Al-Humayyd MS
Biopharm Drug Dispos; 2008 Jan; 29(1):29-35. PubMed ID: 17943700
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration.
Davis JL; Papich MG; Weingarten A
J Vet Pharmacol Ther; 2006 Jun; 29(3):191-7. PubMed ID: 16669863
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.
Guay DR; Awni WM; Peterson PK; Obaid S; Breitenbucher R; Matzke GR
Am J Med; 1987 Apr; 82(4A):124-9. PubMed ID: 3578321
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats.
Marín P; Escudero E; Fernández-Varón E; Cárceles CM
J Vet Pharmacol Ther; 2007 Feb; 30(1):74-9. PubMed ID: 17217405
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of intravenously administered levofloxacin in men and women.
Overholser BR; Kays MB; Lagvankar S; Goldman M; Mueller BA; Sowinski KM
Pharmacotherapy; 2005 Oct; 25(10):1310-8. PubMed ID: 16185174
[TBL] [Abstract][Full Text] [Related]
27. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
29. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
30. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
31. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC.
Khan MK; Khan MF
Pak J Pharm Sci; 2008 Jul; 21(3):299-306. PubMed ID: 18614429
[TBL] [Abstract][Full Text] [Related]
32. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.
Jullien V; Urien S; Hirt D; Delaugerre C; Rey E; Teglas JP; Vaz P; Rouzioux C; Chaix ML; Macassa E; Firtion G; Pons G; Blanche S; Tréluyer JM
Antimicrob Agents Chemother; 2006 Nov; 50(11):3548-55. PubMed ID: 16940058
[TBL] [Abstract][Full Text] [Related]
33. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.
Washington C; Hou SY; Hughes NC; Campanella C; Berner B
J Clin Pharmacol; 2007 Oct; 47(10):1320-6. PubMed ID: 17724088
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects.
Khan MK; Khan MF
Pak J Pharm Sci; 2009 Jan; 22(1):1-7. PubMed ID: 19168412
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
37. Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species.
Cox SK; Cottrell MB; Smith L; Papich MG; Frazier DL; Bartges J
J Vet Pharmacol Ther; 2004 Jun; 27(3):139-46. PubMed ID: 15189299
[TBL] [Abstract][Full Text] [Related]
38. The administration of ciprofloxacin during continuous renal replacement therapy: pilot study.
Hayakawa M; Fujita I; Iseki K; Gando S
ASAIO J; 2009; 55(3):243-5. PubMed ID: 19318919
[TBL] [Abstract][Full Text] [Related]
39. Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis.
Bielecka-Grzela S; Klimowicz A
J Clin Pharm Ther; 2005 Aug; 30(4):383-90. PubMed ID: 15985052
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of erythropoietin in critically ill subjects.
Chakraborty A; Natarajan J; Guilfoyle M; Morgan N; Vercammen E; Cheung W
J Clin Pharmacol; 2005 Feb; 45(2):193-202. PubMed ID: 15647412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
